Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Atara Biotherapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 140 | 1 | 139 | 0 |
| Shares | 89.7M | 77 | 95.2M | +5.47M (+6.1%) |
| Value | $1.61B | $1.00K | $1.50B | −$105.6M (−6.6%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Eminence Capital, LP | 1,141,457 | $18.0M | 0.23% |
| Deep Track Capital, LP | 750,000 | $11.8M | 0.87% |
| M28 Capital Management LP | 456,865 | $7.20M | 5.62% |
| One Fin Capital Management LP | 303,000 | $4.78M | 1.99% |
| Allspring Global Investments Holdings, LLC | 47,498 | $748.0K | 0.00% |
| Engineers Gate Manager LP | 45,670 | $720.0K | 0.03% |
| Prelude Capital Management, LLC | 40,029 | $631.0K | 0.03% |
| Gsa Capital Partners LLP | 24,381 | $384.0K | 0.05% |
| Corton Capital Inc. | 19,408 | $306.0K | 0.14% |
| Bradley Foster & Sargent Inc | 16,581 | $261.0K | 0.01% |
| Letko, Brosseau & Associates Inc | 15,700 | $247.0K | 0.00% |
| Bailard, Inc. | 15,047 | $237.0K | 0.01% |
| AlphaCrest Capital Management LLC | 11,986 | $189.0K | 0.01% |
| Concord Wealth Partners | 44 | $1.00K | 0.00% |
| Covestor Ltd | 34 | $1.00K | 0.00% |
Sold out (15)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Lion Point Capital, LP | 350,465 | $6.27M |
| Renaissance Technologies LLC | 281,679 | $5.04M |
| Two Sigma Investments, LP | 246,136 | $4.41M |
| Los Angeles Capital Management LLC | 24,491 | $438.0K |
| Ergoteles LLC | 20,987 | $376.0K |
| Vontobel Holding Ltd. | 20,000 | $358.0K |
| Group One Trading, L.P. | 13,838 | $248.0K |
| Susquehanna Fundamental Investments, LLC | 10,907 | $195.0K |
| LPL Financial LLC | 10,120 | $181.0K |
| Nisa Investment Advisors, LLC | 4,620 | $83.0K |
| Pacitti Group Inc. | 2,000 | $36.0K |
| Penserra Capital Management LLC | 1,940 | $34.0K |
| IFP Advisors, Inc | 750 | $13.0K |
| Cutler Group LP | 300 | $5.00K |
| Gerber Kawasaki Wealth & Investment Management | 210 | $3.00K |
Not filed for Q4 2021 yet (1)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Berman Capital Advisors, LLC | 77 | $1.00K |